Other Events ·
On September 14, 2026, the U.S. Food and Drug Administration approved Telix Pharmaceuticals' New Drug Application for…
TLPPFTelix Pharmaceuticals Ltd
On September 14, 2026, the U.S. Food and Drug Administration approved Telix Pharmaceuticals' New Drug Application for Pixclara (floretyrosine F 18), marking it as the first FDA-approved PET imaging drug for glioma. This approval addresses a significant unmet need by enabling physicians to differentiate recurrent or progressive brain cancer from treatment-related changes in adults and pediatric patients, aligning with international clinical guidelines such as NCCN. The regulatory milestone expands Telix’s precision medicine portfolio and reinforces its leadership in theranostics. Telix Pharmaceuticals Limited is a commercial-stage global radiopharmaceutical company advancing targeted theranostics to improve outcomes for people with cancer.